This booklet is intended for patients who have been prescribed XALKORI (crizotinib). The patient alert card shown in the booklet is to help patients understand the risks associated with Xalkori, and remind them to seek immediate medical attention if they experience any listed signs and symptoms

Patient alert card for Xarelto 2.5mg, 10mg, 15mg & 20mg - noting patient's anticoagulation treatment

Xarelto Prescriber Guide for Healthcare Professionals

Prescriber brochure to provide guidance on assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan.

Prescriber Initiation checklist to remind HCPs of the risks associated with the use of tofacitinib and the recommended tests before and during tofacitinib administration and treatment

Prescriber Maintenance checklist to remind HCPs of the risks associated with the use of tofacitinib and the recommended tests before and during tofacitinib administration and treatment

Patient alert card to help patients understand the risks associated with XELJANZ, and remind them to seek immediate medical attention if they experience any listed signs and symptoms.

Prescribing checklist before prescribing Xenidate XL 18mg and checklist for ongoing monitoring

Prescribing checklist before prescribing Xenidate XL 27mg and checklist for ongoing monitoring

Prescribing checklist before prescribing Xenidate XL 36mg prolonged-released tablets and checklist for ongoing monitoring

Prescribing checklist before prescribing Xenidate XL 54mg and checklist for ongoing monitoring

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (XGEVA) injections for cancer-related conditions, A side effect called osteonecrosis of the jaw (ONJ, bone damage in the jaw) has been reported commonly (may affect up to 1 in 10 people) in patients receiving XGEVA injections for cancer-related conditions. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

This audio guide was created to help you better understand Ximluci when used for the treatment of neovascular (wet) age-related macular degeneration (AMD) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.

This audio guide was created to help you better understand Ximluci when used for the treatment of visual impairment due to choroidal neovascularisation (CNV) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.

This audio guide was created to help you better understand Ximluci when used for the treatment of proliferative diabetic retinopathy and/or visual impairment due to diabetic macular oedema (DMO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.

This audio guide was created to help you better understand Ximluci when used for the treatment of visual impairment due to retinal vein occlusion (RVO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.

This booklet was created to help you better understand Ximluci when used for the treatment of neovascular (wet) age-related macular degeneration (AMD) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.

This booklet was created to help you better understand Ximluci when used for the treatment of visual impairment due to choroidal neovascularisation (CNV) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.

This booklet was created to help you better understand Ximluci when used for the treatment of proliferative diabetic retinopathy and/or visual impairment due to diabetic macular oedema (DMO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.

This booklet was created to help you better understand Ximluci when used for the treatment of visual impairment due to retinal vein occlusion (RVO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.

Every Xospata 40 mg film-coated tablets pack contains a patient alert card. The purpose of the patient alert card is to provide: -Information for patients that Xospata treatment may cause differentiation syndrome. -Description of signs or symptoms of the safety concern and when to seek medical care if differentiation syndrome is suspected -A warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Xospata. -Contact details of the treating physician who has prescribed Xospata. -Needs to be carried all the time and presented to any healthcare professional.

Guide for Healthcare Professionals:correct use of Xultophy to minimise the risk of medication errors

Xylocaine 10mg Spray is supplied with a single use nozzle for the administration of Xylocaine Spray. A multi-pack of 50 individual nozzles are also available separately. If the nozzles are shared among patients, or reused by individual patients, there is a potential risk of cross contamination. Due to this risk, the Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labelling have been updated with important information on the use of the nozzle.

Important information about safe use and handling of Xyrem

Important risk minimisation information for patients on how to take Xyrem.

Important risk minimisation information for healthcare professionals: Treatment initiation and follow-up visit form

Important safety information for patients and physicians/pharmacists.

Important risk minimisation information for patients: frequently asked questions (FAQ) Information sheet